PharmD Capital Trading with PharmD_KS

PharmD Capital Trading with PharmD_KS

Market Analysis and Trades for 3/24

PharmD_KS's avatar
PharmD_KS
Mar 23, 2026
∙ Paid

If you are looking to join the Discord (now separate from the newsletter) please see here: JOIN THE DISCORD Please email help@pharmdcapital.com if there are any technical issues. Plans/levels will be posted in the Discord so the Discord option includes Substack content but a new Substack subscription does not include Discord access.

Be sure you have read the Starter Kit, including the free section even if you’re a paid subscriber. Trading Doggy Style Starter Kit

The 2026 Equity Markets Year Ahead can be watched here: 2026 Equity Markets Year Ahead

The weekly post for SPY 0.00%↑ and QQQ 0.00%↑ should be reviewed prior to this. It can be found here Market Analysis for the Week of 3/15

After the massive premarket rip on news of potential constructive talks with Iran, both ES and NQ came into massive resistance. If long from premarket that was obviously an amazing trade but it was quite difficult to take part otherwise. After pulling back from resistance, the cash session was reasonably constructive until the return to resistance and LAAF the IB high.

ES was the same idea as a LAAF the IB high so either could have been traded. This was the cleanest setup today and was the only trade I personally took. Ultimately bulls held where they needed to, but today’s weak close puts them at a disadvantage.

I did a public livestream on 3/4 discussing a bit about volume profile, a bit about trading in general, and answered a few questions. The replay can be seen here: March 4th Livestream

I launched a new service offering that can be seen here on X: Doggy Style Daily Degeneracy

Will this morning’s premarket move get completely unwound or are we back to “up only?"

Paid Content Below or in the Discord

JOIN THE DISCORD

PharmD Capital Trading with PharmD_KS is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2026 PharmD_KS · Market data by Intrinio · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture